Monte Rosa Therapeutics, Inc.
GLUE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $611 | $371 | $381 | $426 |
| - Cash | $208 | $69 | $79 | $224 |
| + Debt | $40 | $41 | $42 | $43 |
| Enterprise Value | $442 | $342 | $345 | $245 |
| Revenue | $13 | $23 | $85 | $61 |
| % Growth | -45% | -72.7% | 40% | – |
| Gross Profit | $11 | $23 | $85 | $61 |
| % Margin | 83.6% | 100% | 100% | 100% |
| EBITDA | -$28 | -$13 | $46 | $15 |
| % Margin | -220.6% | -57.9% | 54.3% | 24.8% |
| Net Income | -$27 | -$12 | $47 | $13 |
| % Margin | -212.1% | -53% | 55.2% | 22.2% |
| EPS Diluted | -0.33 | -0.15 | 0.57 | 0.22 |
| % Growth | -120% | -126.3% | 159.1% | – |
| Operating Cash Flow | $100 | -$35 | -$45 | $129 |
| Capital Expenditures | -$1 | -$2 | -$2 | -$0 |
| Free Cash Flow | $100 | -$36 | -$47 | $129 |